This is research, not a buy or sell recommendation. Robo-advice in Taiwan requires an FSC licence; FEAF analyses, explains and monitors, and the investor makes the decision. Judgement thresholds are working rules pending review by the team's finance members.
Plain-language summary of valuation, growth, profitability, balance sheet, and recent MOPS filings.
Your risk profile
Conclusion
Mixed picture: 3 strengths against 3 watch-outs. Weigh them against your own goals.
Points to watch for a moderate profile: see the items marked above.
No model narrative: the model call failed. The structured analysis above is complete on its own.
Strengths
+
The current price implies 0.2% perpetual growth, within the 3.5% ceiling: expectations look attainable. source (Valuation) →
+
Revenue grew 22.2% in 2025; latest quarter Q3 2026: 5.6% year on year. source (Financials) →
+
Free cash flow was positive in 2025: 134 NT$ million. source (Financials) →
Watch-outs
!
P/E 22.37 is well above the Biotechnology and medical median of 15.31 (38 listed peers): priced richer than peers. source (Key Stats) →
!
Return on equity 2.9% with a 4.7% net margin: weak profitability. source (Key Stats) →
!
Liabilities are 53.3% of total assets (Q3 2026): a heavy debt load. source (Financials) →
What to check before deciding
?Why is it priced above its peers, and is that premium justified?
?What would lift profitability, and how soon?
?Can operating cash cover the debt if conditions tighten?